ALK and non-small cell lung carcinoma: It is identified in approximately 3% to 7% of NSCLC patients,[1,2] and is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, ceritinib, brigatinib.[3,4] In the era of cancer precision therapy, with the continuous optimization and update of gene sequencing technology, more and more atypical ALK fusion genes have been detected.